364 related articles for article (PubMed ID: 28638489)
1. Harnessing Integrative Omics to Facilitate Molecular Imaging of the Human Epidermal Growth Factor Receptor Family for Precision Medicine.
Pool M; de Boer HR; Hooge MNL; van Vugt MATM; de Vries EGE
Theranostics; 2017; 7(7):2111-2133. PubMed ID: 28638489
[TBL] [Abstract][Full Text] [Related]
2. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL
Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505
[TBL] [Abstract][Full Text] [Related]
3. Imaging of human epidermal growth factor receptors for patient selection and response monitoring - From PET imaging and beyond.
Pereira PMR; Abma L; Henry KE; Lewis JS
Cancer Lett; 2018 Apr; 419():139-151. PubMed ID: 29414302
[TBL] [Abstract][Full Text] [Related]
4. Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification.
Oh DY; Jung K; Song JY; Kim S; Shin S; Kwon YJ; Oh E; Park WY; Song SY; Choi YL
BMC Cancer; 2017 Aug; 17(1):535. PubMed ID: 28806950
[TBL] [Abstract][Full Text] [Related]
5. A role for the pseudokinase HER3 in the acquired resistance against EGFR- and HER2-directed targeted therapy.
Claus J; Patel G; Ng T; Parker PJ
Biochem Soc Trans; 2014 Aug; 42(4):831-6. PubMed ID: 25109965
[TBL] [Abstract][Full Text] [Related]
6. PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology.
Rinne SS; Orlova A; Tolmachev V
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33915894
[TBL] [Abstract][Full Text] [Related]
7. Making Molecular Imaging a Clinical Tool for Precision Oncology: A Review.
Mankoff DA; Farwell MD; Clark AS; Pryma DA
JAMA Oncol; 2017 May; 3(5):695-701. PubMed ID: 28033451
[TBL] [Abstract][Full Text] [Related]
8. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
Jotte RM; Spigel DR
Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor imaging in human head and neck cancer xenografts.
van Dijk LK; Boerman OC; Kaanders JH; Bussink J
Acta Oncol; 2015; 54(9):1263-7. PubMed ID: 26248024
[TBL] [Abstract][Full Text] [Related]
10. Developments for Personalized Medicine of Lung Cancer Subtypes: Mass Spectrometry-Based Clinical Proteogenomic Analysis of Oncogenic Mutations.
Nishimura T; Nakamura H
Adv Exp Med Biol; 2016; 926():115-137. PubMed ID: 27686809
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Molecular Imaging for Precision Medicine in Breast Cancer Mouse Models.
Fiordelisi MF; Auletta L; Meomartino L; Basso L; Fatone G; Salvatore M; Mancini M; Greco A
Contrast Media Mol Imaging; 2019; 2019():8946729. PubMed ID: 31598114
[TBL] [Abstract][Full Text] [Related]
12. Molecular imaging of targeted therapies with positron emission tomography: the visualization of personalized cancer care.
Mammatas LH; Verheul HM; Hendrikse NH; Yaqub M; Lammertsma AA; Menke-van der Houven van Oordt CW
Cell Oncol (Dordr); 2015 Feb; 38(1):49-64. PubMed ID: 25248503
[TBL] [Abstract][Full Text] [Related]
13. Identification of Disease States and Response to Therapy in Humans by Utilizing the Biomarker EGFR for Targeted Molecular Imaging.
Sun X; Li S; Shen B
Curr Protein Pept Sci; 2016; 17(6):534-42. PubMed ID: 26721405
[TBL] [Abstract][Full Text] [Related]
14. Colorectal cancer spheroid biobanks: multi-level approaches to drug sensitivity studies.
De Angelis ML; Bruselles A; Francescangeli F; Pucilli F; Vitale S; Zeuner A; Tartaglia M; Baiocchi M
Cell Biol Toxicol; 2018 Dec; 34(6):459-469. PubMed ID: 29478126
[TBL] [Abstract][Full Text] [Related]
15. Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers.
Osada T; Hartman ZC; Wei J; Lei G; Hobeika AC; Gwin WR; Diniz MA; Spector N; Clay TM; Chen W; Morse MA; Lyerly HK
Breast Cancer Res; 2018 Aug; 20(1):90. PubMed ID: 30092835
[TBL] [Abstract][Full Text] [Related]
16. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
[TBL] [Abstract][Full Text] [Related]
17. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
18. Targeted dual degradation of HER2 and EGFR obliterates oncogenic signaling, overcomes therapy resistance, and inhibits metastatic lesions in HER2-positive breast cancer models.
Yang L; Bhattacharya A; Peterson D; Li Y; Liu X; Marangoni E; Robila V; Zhang Y
Drug Resist Updat; 2024 May; 74():101078. PubMed ID: 38503142
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy.
Gazdar AF
Cancer Metastasis Rev; 2010 Mar; 29(1):37-48. PubMed ID: 20127143
[TBL] [Abstract][Full Text] [Related]
20. Drug-biomarker co-development in oncology - 20 years and counting.
Twomey JD; Brahme NN; Zhang B
Drug Resist Updat; 2017 Jan; 30():48-62. PubMed ID: 28363335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
